Study Details

Open

Phase 2 Relapsed or Refractory Multiple Myeloma Study

This is a study for patients with relapsed or refractory multiple myeloma (MM). In this study we want to learn more about the effectiveness of a treatment called BMS-986393. BMS-986393 is a type of treatment known as chimeric antigen receptor (CAR) T-cell therapy, which is a modified form of your own T-cells that may recognize and destroy your cancer cells. This is a single-therapy study.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Visit Availability

Visits can be combined with regular clinical appointments

Location

North Carolina (Statewide)

What will be asked of you

The following tests will take place at various times during your participation: health evaluation and medical history, routine or symptom-directed physical examination and vital signs, routine neurological examination, Graft Versus Host Disease (GVHD) assessment, Immune Effector Cell Associated Encephalopathy (ICE) assessment, cardiac assessment, imaging assessment (X-rays, PET scans, CT scans, or MRI), 24-hour urine collection, blood samples for routine assessments, blood samples for study tests, bone marrow assessments, tissue biopsy, health care utilization, quality of life assessments, wearable biosensors.

Incentives

Prepaid travel arrangements and expense reimbursements are available through a Travel Assistance Program offered by Clincierge. You will not need to pay for study treatment, study visits, or medical tests needed specifically for this study.

Total length of participation:
approximately 74 months

Looking for Specific Volunteers

Able to participate:

You have documented diagnosis of multiple myeloma as per IMWG criteria.
You have received at least three lines of therapy.
You have received at least four prior classes of multiple myeloma treatment.
You have documented disease progression during or after your last antimyeloma regimen.
You have measurable disease during screening.

Not eligible if:

You have known active or history of central nervous system (CNS) involvement of multiple myeloma.
You require urgent therapy due to rapidly progressing disease.
You have evidence of human immunodeficiency virus (HIV) infection or an active hepatitis B virus or hepatitis C virus infection.
You have an active autoimmune disease requiring systemic immunosuppressive therapy.
You have received prior therapy directed at GPRC5D

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Lineberger Clinical Research
cancerclinicaltrials@med.unc.edu
(919) 966-4432

Primary Visit Location

NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Secondary Visit Location

UNC Hospitals Hillsborough Campus
460 Waterstone Dr, Hillsborough, NC 27278, USA

Additional Study Information

Principal Investigator

Eben Lichtman
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Multiple Myeloma)

IRB Number

23-3299